Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865054 | 0.80 | LMNA (0.38) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL4274877 | 0.80 | HSP90AA1 (0.43) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL5606343 | 0.80 | HSP90AA1 (0.43) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL15392290 | 0.80 | HSP90AA1 (0.44) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL22820306 | 0.78 | CCR1 (0.39) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL1056427 | 0.77 | AGXT (0.69) | AGXTHSP90AA1HSP90AB1 | |
| SCHEMBL2095358 | 0.76 | HSP90AA1 (0.39) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL3396036 | 0.76 | CCR1 (0.38) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL1758565 | 0.76 | AGXT (0.40) | AGXTHSP90AA1HSP90AB1CCR1CCR5 | |
| SCHEMBL9828008 | 0.76 | HSP90AA1 (0.39) | AGXTHSP90AA1HSP90AB1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | claimed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | claimed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2865446-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | KANTO KAGAKU (JP) | 2021-09-22 | — | — | EP | disclosed |
| US-20160311795-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | CALASIA PHARMACEUTICALS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-20160311795-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | CALASIA PHARMACEUTICALS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-9174906-B2 | Process for producing optically active secondary alcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2865446-A1 | Process for producing optically active secondary alcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031920-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL | ADH1A, ADH1C, ADH5 | AGXT 1356/4885HSP90AA1 3336/4885HSP90AB1 2440/4885 |
| US-20070253896-A1 | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | HSP90B1, HSP90AB2P, HSP90AB1 | AGXT 3755/4885HSP90AA1 4/4885HSP90AB1 3/4885 |
| US-20160311795-A1 | PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 | HSP90B1, HSP90AB2P, HSPE1 | AGXT 2147/4885HSP90AA1 5/4885HSP90AB1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.